T-Cure Partners With Atlas to Develop a KK-LC-1 Diagnostic Test
On Tuesday, October 5, T-Cure announced (press release) a collaborative agreement with Atlas Antibodies for the development, manufacture, and supply of CT83 (KK-LC-1-directed monoclonal antibody). Of note, CT83 will be used for the development of a diagnostic test to identify KK-LC-1-expressing tumors. Below, Celltelligence provides insights on how the use of a companion diagnostic test could improve clinical outcomes, while discussing T-Cure’s novel TCR-T pipeline.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.